Fate Therapeutics (NASDAQ:FATE) granted new employee equity awards under Nasdaq Listing Rule 5635(c)(4).
On June 1, 2026, two newly hired non-executive employees received RSUs covering 67,300 common shares under the company’s Amended and Restated Inducement Equity Plan, vesting over four years in 25% annual installments.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
None.
Negative
None.
News Market Reaction – FATE
-13.62%
37 alerts
-13.62%News Effect
-15.1%Trough in 28 hr 58 min
-$47MValuation Impact
$300.72MMarket Cap
1.2xRel. Volume
On the day this news was published, FATE declined 13.62%, reflecting a significant negative market reaction.
Argus tracked a trough of -15.1% from its starting point during tracking.
Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility.
This price movement removed approximately $47M from the company's valuation, bringing the market cap to $300.72M at that time.
RSU grant size:67,300 sharesNumber of employees:2 employeesVesting period:4 years+3 more
6 metrics
RSU grant size67,300 sharesRestricted stock units to two newly hired non-executive employees
Number of employees2 employeesRecipients of the inducement RSU grants
Vesting period4 yearsRSUs vesting schedule under inducement equity plan
Annual vesting rate25% per yearPortion of each RSU award vesting on each anniversary
Current price$2.74Price before publication of inducement grant news
52-week range$0.91–$2.88Low and high prior to this announcement
Market Reality Check
Price:$2.22Vol:Volume 7,427,677 vs 20-da...
normal vol
$2.22Last Close
VolumeVolume 7,427,677 vs 20-day avg 5,177,877 (relative volume 1.43) ahead of this routine HR update.normal
TechnicalShares at $2.74 are trading above the $1.29 200-day MA and sit 4.86% below the 52-week high of $2.88.
Peers on Argus
FATE is down 3.52% while peers show mixed moves: EQ up 6.21%, CRBP, FBRX, KALA, ...
FATE is down 3.52% while peers show mixed moves: EQ up 6.21%, CRBP, FBRX, KALA, and TARA modestly negative. No broad, aligned sector move is evident.
Common CatalystBoth FATE and peer EQ reported Nasdaq Listing Rule 5635(c)(4) inducement grants, suggesting a governance/HR-related theme rather than a fundamental pipeline catalyst.
FT819 selected for FDA CMC Development and Readiness Pilot program.
Pattern Detected
Recent history shows frequent negative reactions to generally positive clinical and corporate updates, with only two of five events aligning positively with sentiment.
Recent Company History
Over the last month, FATE has reported multiple pipeline milestones and financial updates. On May 5, FDA CDRP selection for FT819 coincided with a 31.11% gain, while ASCO/EULAR presentation news on May 21 saw a 14.13% rise. In contrast, Q1 2026 results on May 13, ASGCT data on May 11, and FT836 ASCO data on June 1 were followed by declines. Today’s small inducement award fits into an active news flow but is less material than recent clinical and regulatory catalysts.
Market Pulse Summary
The stock dropped -13.6% in the session following this news. A negative reaction despite neutral HR-...
Analysis
The stock dropped -13.6% in the session following this news. A negative reaction despite neutral HR-related news fits a pattern where FATE has sometimes declined after generally positive updates, such as clinical data or earnings. The current item involves inducement RSU awards of 67,300 shares under Nasdaq Listing Rule 5635(c)(4), which is relatively small versus the company’s overall equity profile. Historically, moves of -5.11% and -8.79% followed substantive announcements, so any sizeable drop here would likely be interpreted within that broader volatility profile.
"the Company granted restricted stock units (RSUs) representing 67,300 shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
rsusfinancial
"The RSUs will vest over four years, with 25% of the shares underlying each RSU award"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
nasdaq listing rule 5635(c)(4)regulatory
"as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement equity planfinancial
"granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material"
An inducement equity plan is a program that offers employees or executives new stock options or shares as a way to encourage them to join or stay with a company. It acts like a reward or incentive to motivate performance and loyalty, aligning their interests with the company's success. For investors, such plans can influence a company's share structure and future earnings, making them an important factor to consider.
induced pluripotent stem cell (ipsc)medical
"a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies"
Induced pluripotent stem cells (iPSCs) are adult cells that scientists have reprogrammed to behave like embryonic stem cells, able to develop into many different cell types. Think of them as retrained workers who can be reassigned to multiple jobs; for investors they matter because iPSCs enable development of new therapies, personalized drug testing, and scaled cell products, which can drive long-term value but also face lengthy development timelines and regulatory scrutiny.
cellular immunotherapiesmedical
"iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases"
Cellular immunotherapies are medical treatments that use living immune cells, taken from a patient or donor and then trained, modified, or expanded in a lab so they better recognize and attack disease, such as cancer or infection. For investors, these therapies matter because they can offer dramatic, durable patient responses and premium pricing but also carry high development, manufacturing and regulatory risks—think of them as highly trained sniffer dogs that can be powerful but expensive and complex to deploy.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, today announced that on June 1, 2026, the Company granted restricted stock units (RSUs) representing 67,300 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.
About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Ryan Douglas Fate Therapeutics, Inc. IR@fatetherapeutics.com
FAQ
What employee inducement awards did Fate Therapeutics (FATE) grant on June 1, 2026?
Fate Therapeutics granted restricted stock units representing 67,300 common shares to two newly hired non-executive employees. According to the company, these RSUs were issued under its Amended and Restated Inducement Equity Plan as a material inducement to join the firm.
How do the new Fate Therapeutics (FATE) RSUs vest for the two employees?
The new Fate Therapeutics RSUs vest over four years in equal annual installments. According to the company, 25% of the shares underlying each RSU award vest on each anniversary of the June 1, 2026 grant date, contingent on continued employment.
Why were the Fate Therapeutics (FATE) inducement RSUs granted under Nasdaq Listing Rule 5635(c)(4)?
The RSUs were granted as inducement awards permitted under Nasdaq Listing Rule 5635(c)(4). According to Fate Therapeutics, they were considered a material inducement for the two non-executive employees to enter into employment and were approved by the board’s Compensation Committee.
How many Fate Therapeutics (FATE) shares are covered by the June 2026 inducement RSUs?
The June 2026 inducement grants cover 67,300 shares of Fate Therapeutics common stock. According to the company, these shares are represented by RSUs awarded to two newly hired non-executive employees as part of their equity compensation package.
Who approved the June 1, 2026 inducement RSU awards at Fate Therapeutics (FATE)?
The Compensation Committee of Fate Therapeutics’ Board of Directors approved the inducement RSU awards. According to the company, this committee authorized the grants under the Amended and Restated Inducement Equity Plan in line with Nasdaq Listing Rule 5635(c)(4).
